EP.132Central Core Myopathy in Chinese Patients with Nav1.4 P.r675q Mutation

J. Sun,S. Luo,M. Gao,K. Qiao,H. Lv,C. Zhao
DOI: https://doi.org/10.1016/j.nmd.2019.06.589
IF: 3.538
2019-01-01
Neuromuscular Disorders
Abstract:Nav1.4 (SCN4A) p.R675Q is the most common mutation in Chinese patients with skeletal muscle sodium channelopathies. Two patients with R675Q mutation from different neuromuscular diagnosis centers complained of fixed myopathy and recurrent periodic paralysis. Muscle biopsy on biceps were performed for both patients. Clinical features as well as muscle MRI in bilateral lower limbs were retrospectively reviewed. To further explore the underlying mechanism of the central core-like pathology, we performed the immunofluorescence staining (IF) and western blot of Ryanodine receptor-1 (RYR1) and calcium channel voltage-dependent L-type alpha 1S unit (Cav1.1) using muscle specimens. Patient 1 was a 21-year-old male presenting periodic paralysis for over 7 years. Muscle weakness mainly involved bilateral lower limbs and the serum potassium level remained normal. The grandpa reported recurrent paralysis at the early age but other family members did not complain of any neuromuscular abnormalities. Patient 2 was a 28-year-old male with periodic paralysis for 14 years. He had 1-3 episodes per year and the serum potassium was at normal range. The father and a brother in the family tree shared similar clinical presentations. Muscle MRI of bilateral limbs revealed medium gastrocnemius and soleus was selectively involved. Histochemical staining of muscle specimens revealed central core or multi-mini core-like structures in most fibers for Patient 1 and 2 (P1, P2). A patient with periodic paralysis due to p.R675Q mutation but no fixed myopathy was also included in the study (P3). IF staining revealed misdistribution of RYR1 and Cav1.1 protein in comparison to normal control and P3. But still RYR1 and Cav1.1 merged well together. Western blot demonstrated secondary reduction of RYR1 in patients 1 and 3. Misdistribution and secondary reduction of RYR1 may be the underlying mechanism of patients with Nav1.4 R675Q mutation.
What problem does this paper attempt to address?